Compounds > 5-(4-ethylbenzylidene)-2-thioxothiazolidin-4-one

5-(4-ethylbenzylidene)-2-thioxothiazolidin-4-one and Leukemia--Myelogenous--Chronic--BCR-ABL-Positive

5-(4-ethylbenzylidene)-2-thioxothiazolidin-4-one has been researched along with Leukemia--Myelogenous--Chronic--BCR-ABL-Positive* in 1 studies

Other Studies

1 other study(ies) available for 5-(4-ethylbenzylidene)-2-thioxothiazolidin-4-one and Leukemia--Myelogenous--Chronic--BCR-ABL-Positive

Article	Year
c-Myc inhibition decreases CIP2A and reduces BCR-ABL1 tyrosine kinase activity in chronic myeloid leukemia. Haematologica, 2015, Volume: 100, Issue:5 Topics: Autoantigens; Cell Line, Tumor; Enzyme Activation; Fusion Proteins, bcr-abl; Humans; Intracellular Signaling Peptides and Proteins; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Membrane Proteins; Proto-Oncogene Proteins c-myc; RNA Interference; RNA, Small Interfering; Thiazoles	2015

Article

Year

c-Myc inhibition decreases CIP2A and reduces BCR-ABL1 tyrosine kinase activity in chronic myeloid leukemia.

Haematologica, 2015, Volume: 100, Issue:5

Topics: Autoantigens; Cell Line, Tumor; Enzyme Activation; Fusion Proteins, bcr-abl; Humans; Intracellular Signaling Peptides and Proteins; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Membrane Proteins; Proto-Oncogene Proteins c-myc; RNA Interference; RNA, Small Interfering; Thiazoles

2015